Drug class in one race
EGFR drugs for Non-Small Cell Lung Cancer
42 tracked EGFR drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the EGFR page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
4 approved / phase 414 Phase 32 Phase 2/34 Phase 213 Phase 1/25 Phase 1
Head-to-head evidence: ALX2004 vs AZD3759 · Almonertinib vs ALX2004 · ALX2004 vs Ametinib · ALX2004 vs BEBT-109 · ALX2004 vs BPI-361175 · ALX2004 vs BPI-7711